These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 29393469)

  • 21. Genetic and Methylation-Induced Loss of miR-181a2/181b2 within chr9q33.3 Facilitates Tumor Growth of Cervical Cancer through the PIK3R3/Akt/FoxO Signaling Pathway.
    Mei Q; Li X; Zhang K; Wu Z; Li X; Meng Y; Guo M; Luo G; Fu X; Han W
    Clin Cancer Res; 2017 Jan; 23(2):575-586. PubMed ID: 27503199
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1.
    Alshaker H; Wang Q; Kawano Y; Arafat T; Böhler T; Winkler M; Cooper C; Pchejetski D
    Oncotarget; 2016 Dec; 7(49):80943-80956. PubMed ID: 27821815
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
    Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
    Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The complexity of TRIM28 contribution to cancer.
    Czerwińska P; Mazurek S; Wiznerowicz M
    J Biomed Sci; 2017 Aug; 24(1):63. PubMed ID: 28851455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TRIM28 represses renal cell carcinoma cell proliferation by inhibiting TFE3/KDM6A-regulated autophagy.
    Song T; Lv S; Ma X; Zhao X; Fan L; Zou Q; Li N; Yan Y; Zhang W; Sun L
    J Biol Chem; 2023 May; 299(5):104621. PubMed ID: 36935008
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers.
    Hatem R; El Botty R; Chateau-Joubert S; Servely JL; Labiod D; de Plater L; Assayag F; Coussy F; Callens C; Vacher S; Reyal F; Cosulich S; Diéras V; Bièche I; Marangoni E
    Oncotarget; 2016 Jul; 7(30):48206-48219. PubMed ID: 27374081
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tripartite motif containing 62 is a novel prognostic marker and suppresses tumor metastasis via c-Jun/Slug signaling-mediated epithelial-mesenchymal transition in cervical cancer.
    Liu TY; Chen J; Shang CL; Shen HW; Huang JM; Liang YC; Wang W; Zhao YH; Liu D; Shu M; Guo LY; Hu Z; Yao SZ
    J Exp Clin Cancer Res; 2016 Oct; 35(1):170. PubMed ID: 27793172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
    François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diminished DYRK2 sensitizes hormone receptor-positive breast cancer to everolimus by the escape from degrading mTOR.
    Mimoto R; Nihira NT; Hirooka S; Takeyama H; Yoshida K
    Cancer Lett; 2017 Jan; 384():27-38. PubMed ID: 27746162
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TRIM28 as an independent prognostic marker plays critical roles in glioma progression.
    Qi ZX; Cai JJ; Chen LC; Yue Q; Gong Y; Yao Y; Mao Y
    J Neurooncol; 2016 Jan; 126(1):19-26. PubMed ID: 26476730
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TRIM28 is a transcriptional activator of the mutant TERT promoter in human bladder cancer.
    Agarwal N; Rinaldetti S; Cheikh BB; Zhou Q; Hass EP; Jones RT; Joshi M; LaBarbera DV; Knott SRV; Cech TR; Theodorescu D
    Proc Natl Acad Sci U S A; 2021 Sep; 118(38):. PubMed ID: 34518220
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The inhibitory effects of carnosic acid on cervical cancer cells growth by promoting apoptosis via ROS-regulated signaling pathway.
    Su K; Wang CF; Zhang Y; Cai YJ; Zhang YY; Zhao Q
    Biomed Pharmacother; 2016 Aug; 82():180-91. PubMed ID: 27470354
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum miR-486-5p as a diagnostic marker in cervical cancer: with investigation of potential mechanisms.
    Li C; Zheng X; Li W; Bai F; Lyu J; Meng QH
    BMC Cancer; 2018 Jan; 18(1):61. PubMed ID: 29316891
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Loss of AIM2 expression promotes hepatocarcinoma progression through activation of mTOR-S6K1 pathway.
    Ma X; Guo P; Qiu Y; Mu K; Zhu L; Zhao W; Li T; Han L
    Oncotarget; 2016 Jun; 7(24):36185-36197. PubMed ID: 27167192
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-tumor effect of the mammalian target of rapamycin inhibitor everolimus in oral squamous cell carcinoma.
    Naruse T; Yanamoto S; Yamada S; Rokutanda S; Kawakita A; Kawasaki G; Umeda M
    Pathol Oncol Res; 2015 Jul; 21(3):765-73. PubMed ID: 25682238
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
    Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
    PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MicroRNA-26a inhibits cell proliferation and invasion of cervical cancer cells by targeting protein tyrosine phosphatase type IVA 1.
    Dong J; Sui L; Wang Q; Chen M; Sun H
    Mol Med Rep; 2014 Sep; 10(3):1426-32. PubMed ID: 24939702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of TRIM28 correlates with proliferation and Bortezomib-induced apoptosis in B-cell non-Hodgkin lymphoma.
    Zhang PP; Ding DZ; Shi B; Zhang SQ; Gu LL; Wang YC; Cheng C
    Leuk Lymphoma; 2018 Nov; 59(11):2639-2649. PubMed ID: 29569972
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tripartite motif-containing protein 3 plays a role of tumor inhibitor in cervical cancer.
    Song Y; Guo Q; Gao S; Hua K
    Biochem Biophys Res Commun; 2018 Apr; 498(3):686-692. PubMed ID: 29524410
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
    Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
    Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.